Clinical Trials Directory

Trials / Completed

CompletedNCT03536637

DMT310-001 Topical in the Treatment of Acne Vulgaris

A Study of Tolerability, Safety, And Efficacy, of DMT310 In Patients With Acne Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
121 (actual)
Sponsor
Dermata Therapeutics · Industry
Sex
All
Age
12 Years
Healthy volunteers
Not accepted

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

Conditions

Interventions

TypeNameDescription
DRUGDMT310Topical Powder
DRUGHydrogen PeroxideLiquid Diluent
DRUGPlaceboPlacebo Topical Powder

Timeline

Start date
2018-05-22
Primary completion
2018-12-30
Completion
2019-01-28
First posted
2018-05-25
Last updated
2020-07-22

Locations

9 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03536637. Inclusion in this directory is not an endorsement.

DMT310-001 Topical in the Treatment of Acne Vulgaris (NCT03536637) · Clinical Trials Directory